Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 106, Issue 1, 2014, Pages 19-26

  Wang, Zheng ^a,b   Lai, Song tao ^a,b   Xie, Li ^a,b   Zhao, Jian dong ^a,b   Ma, Ning yi ^a,b   Zhu, Ji ^a,b   Ren, Zhi gang ^a,b   Jiang, Guo liang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Meta analysis; Metformin; Pancreatic cancer

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PANCREAS CANCER; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; PANCREATIC NEOPLASMS; PROGNOSIS; RISK ASSESSMENT;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PANCREATIC NEOPLASMS; PROGNOSIS; RISK ASSESSMENT;

EID: 84908028466     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.007     Document Type: Review

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: Cancer J Clin 2012, 62:10-29.
2. Andriulli A., Festa V., Botteri E., Valvano M.R., Koch M., Bassi C., et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012, 19:1644-1662.
3. Davis J.L., Pandalai P.K., Ripley R.T., Langan R.C., Avital I. Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy. Pancreas 2012, 41:678-684.
4. Nentwich M.F., Bockhorn M., Konig A., Izbicki J.R., Cataldegirmen G. Surgery for advanced and metastatic pancreatic cancer-current state and trends. Anticancer Res 2012, 32:1999-2002.
5. McAuliffe J.C., Christein J.D. Type 2 diabetes mellitus and pancreatic cancer. Surg Clin N Am 2013, 93:619-627.
6. Pannala R., Basu A., Petersen G.M., Chari S.T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10:88-95.
7. Bartosch-Harlid A., Andersson R. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatol: Off J Int Assoc Pancreatol 2010, 10:423-428.
8. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
9. Ben Sahra I., Le Marchand-Brustel Y., Tanti J.F., Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol Cancer Ther 2010, 9:1092-1099.
10. Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18:2723-2725.
11. Bao B., Wang Z., Ali S., Ahmad A., Azmi A.S., Sarkar S.H., et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 2012, 5:355-364.
12. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
13. Bednar F., Simeone D.M. Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res 2012, 5:351-354.
14. Kisfalvi K., Moro A., Sinnett-Smith J., Eibl G., Rozengurt E. Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 2013, 42:781-785.
15. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010, 3:1451-1461.
16. Noto H., Goto A., Tsujimoto T., Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PloS ONE 2012, 7:e33411.
17. Guyatt G.H., Oxman A.D., Vist G., Kunz R., Brozek J., Alonso-Coello P., et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011, 64:407-415.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
20. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
21. Oliveria S.A., Koro C.E., Ulcickas Yood M., Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr: Clin Res Rev 2008, 2:47-57.
22. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
23. Ferrara A., Lewis J.D., Quesenberry C.P., Peng T., Strom B.L., Van Den Eeden S.K., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34:923-929.
24. Morden N.E., Liu S.K., Smith J., Mackenzie T.A., Skinner J., Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011, 34:1965-1971.
25. Lee M.S., Hsu C.C., Wahlqvist M.L., Tsai H.N., Chang Y.H. BMC Cancer 2011, 11:20.
26. Liao K.F., Lai S.W., Li C.I., Chen W.C. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012, 27:709-713.
27. Ruiter R., Visser L.E., van Herk-Sukel M.P., Coebergh J.W., Haak H.R., Geelhoed-Duijvestijn P.H., et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012, 35:119-124.
28. Hsieh M.C., Lee T.C., Cheng S.M., Tu S.T., Yen M.H., Tseng C.H. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012, 2012:413782.
29. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
30. Little M.W., Pugh T.F., Carey F.J., Ndokera R., Ing H., Robinson R.J., et al. The potential protective effect of metformin against pancreatic cancer: preliminary results from a case-control study in two UK centres. Gut 2011, 60.
31. Bodmer M., Becker C., Meier C., Jick S.S., Meier C.R. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012, 107:620-626.
32. Col N.F., Ochs L., Springmann V., Aragaki A.K., Chlebowski R.T. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012, 135:639-646.
33. Zhang Z.J., Zheng Z.J., Shi R., Su Q., Jiang Q., Kip K.E. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012, 97:2347-2353.
34. Zhang Z.J., Zheng Z.J., Kan H., Song Y., Cui W., Zhao G., et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011, 34:2323-2328.
35. Smiechowski B.B., Azoulay L., Yin H., Pollak M.N., Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013, 36:124-129.
36. Sadeghi N., Abbruzzese J.L., Yeung S.C., Hassan M., Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18:2905-2912.
37. Karnevi E., Said K., Andersson R., Rosendahl A.H. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 2013, 13:235.
38. Sinnett-Smith J., Kisfalvi K., Kui R., Rozengurt E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 2013, 430:352-357.
39. Wang L.W., Li Z.S., Zou D.W., Jin Z.D., Gao J., Xu G.M. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008, 14:7192-7198.
40. Kourelis T.V., Siegel R.D. Metformin and cancer: new applications for an old drug. Med Oncol 2012, 29:1314-1327.
41. Li W., Yuan Y., Huang L., Qiao M., Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012, 96:187-195.
42. Gou S., Cui P., Li X., Shi P., Liu T., Wang C. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PloS ONE 2013, 8:e63969.
43. Dong L., Zhou Q., Zhang Z., Zhu Y., Duan T., Feng Y. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res 2012, 38:1077-1085.
44. Kawanami T., Takiguchi S., Ikeda N., Funakoshi A. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncol Rep 2012, 27:867-872.
45. Song C.W., Lee H., Dings R.P., Williams B., Powers J., Santos T.D., et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012, 2:362.
46. Storozhuk Y., Hopmans S.N., Sanli T., Barron C., Tsiani E., Cutz J.C., et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 2013, 108:2021-2032.
47. Baur D.M., Klotsche J., Hamnvik O.P., Sievers C., Pieper L., Wittchen H.U., et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metab: Clin Exp 2011, 60:1363-1371.